文献速递肿瘤 PET/CT

比较以NOTA和DOTA作为双功能螯合剂的64Cu-DOTA-PSMA-3Q与64Cu-NOTA-PSMA-3Q在前列腺癌中的应用:临床前评估与初步临床PET/CT显像

Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-15

本研究比较了以NOTA和DOTA为双功能螯合剂制备的64Cu-DOTA-PSMA-3Q与64Cu-NOTA-PSMA-3Q的稳定性、生物分布及临床PET/CT显像表现,临床前研究显示两者放化纯度均超过98%且体外稳定性良好,荷瘤小鼠中DOTA标记物在注射后24小时肿瘤滞留显著更优,23例疑似前列腺癌患者PET/CT未观察到不良反应或生命体征显著变化,NOTA标记物肝摄取显著低于DOTA标记物但唾液腺摄取更高。

要点

  • 64Cu-DOTA-PSMA-3Q与64Cu-NOTA-PSMA-3Q放化纯度均超过98%,体外稳定性良好。
  • 荷瘤小鼠中DOTA标记物注射后24小时肿瘤滞留显著优于NOTA标记物。
  • 23例疑似前列腺癌患者PET/CT未见不良反应,NOTA标记物肝摄取显著低于DOTA标记物。

核心结论

  • NOTA和DOTA均为开发64Cu标记PSMA-3Q PET/CT显像剂的合适螯合剂。
  • DOTA标记物在注射后24小时显示更好的肿瘤滞留,NOTA标记物肝摄取更低但唾液腺摄取更高。
  • 选择合适螯合剂对优化临床显像结果具有重要意义。

研究设计与样本

  • 研究为临床前评估加初步临床PET/CT显像,64Cu-DOTA-PSMA-3Q与64Cu-NOTA-PSMA-3Q通过手动标记合成。
  • 临床前研究评估放化纯度、稳定性、特异性及生物分布,并进行健康小鼠生物分布研究和22Rv1荷瘤小鼠micro-PET/CT显像。
  • 临床部分纳入23例疑似前列腺癌患者,采用PET/CT显像评估两种示踪剂的生物分布潜力与差异。
  • 试验注册于中国临床试验注册中心,注册号ChiCTR2300072655,注册日期2023年6月20日。

主要发现

  • 64Cu-DOTA-PSMA-3Q与64Cu-NOTA-PSMA-3Q放化纯度均超过98%,体外稳定性良好。
  • 健康小鼠生物分布显示两种示踪剂注射后主要经肾脏排泄,注射后1小时64Cu-DOTA-PSMA-3Q肝摄取显著高于64Cu-NOTA-PSMA-3Q(P<0.05)。
  • 22Rv1荷瘤小鼠micro-PET/CT显示注射后1小时两种示踪剂肿瘤摄取相似(P>0.05),注射后24小时64Cu-DOTA-PSMA-3Q肿瘤滞留显著优于64Cu-NOTA-PSMA-3Q(P<0.05)。
  • 23例疑似前列腺癌患者PET/CT显像未观察到不良反应或生命体征显著变化;64Cu-NOTA-PSMA-3Q在泪腺(17.73 vs. 10.84)、腮腺(20.98 vs. 16.30)和下颌下腺(20.26 vs. 17.28)摄取高于64Cu-DOTA-PSMA-3Q,舌下腺摄取较低(7.10 vs. 7.49),肝摄取显著低于64Cu-DOTA-PSMA-3Q(4.04 vs. 8.18)。

关键数值与推荐

  • 64Cu-DOTA-PSMA-3Q与64Cu-NOTA-PSMA-3Q放化纯度均超过98%。
  • 注射后1小时64Cu-DOTA-PSMA-3Q肝摄取显著高于64Cu-NOTA-PSMA-3Q(P<0.05)。
  • 注射后1小时两种示踪剂肿瘤摄取相似(P>0.05),注射后24小时64Cu-DOTA-PSMA-3Q肿瘤滞留显著优于64Cu-NOTA-PSMA-3Q(P<0.05)。
  • 临床PET/CT中64Cu-NOTA-PSMA-3Q肝摄取显著低于64Cu-DOTA-PSMA-3Q(4.04 vs. 8.18)。

临床怎么用

  • 作者认为NOTA和DOTA均适用于开发64Cu标记PSMA-3Q PET/CT显像剂。
  • 作者指出DOTA标记物注射后24小时肿瘤滞留更好,NOTA标记物肝摄取更低但唾液腺摄取更高,螯合剂选择可影响显像结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to investigate the efficacy and safety of prostate-specific membrane antigen (PSMA) radiolabeled with copper-64 (64Cu) using the bifunctional chelating agents (BFCAs) NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). As widely utilized BFCAs in the development of radiopharmaceuticals, NOTA and DOTA play a critical role in ensuring stable chelation with 64Cu. This study evaluates the stability, bioavailability, and therapeutic potential of these radiolabeled compounds in preclinical models and initial clinical trials. METHODS: 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q were synthesized by manual labeling. The radiochemical purity, stability, specificity and biological distribution of the product were evaluated by preclinical studies. In 23 patients with suspected prostate cancer, PET/CT imaging was used to evaluate the potential and differences in biological distribution of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q in clinical diagnosis. RESULTS: The radiochemical purities of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q are more than 98% and have good stability in vitro. Biodistribution studies in healthy mice revealed that both tracers primarily underwent renal excretion post-injection. Liver uptake of 64Cu-DOTA-PSMA-3Q was significantly higher than that of 64Cu-NOTA-PSMA-3Q at 1 h after injection (P<0.05). Micro-PET/CT imaging in 22Rv1 tumor-bearing mice demonstrated similar tumor uptake for both tracers at 1 h after injection (P>0.05). However, after 24 h, 64Cu-DOTA-PSMA-3Q exhibited significantly better tumor retention compared to 64Cu-NOTA-PSMA-3Q (P<0.05). In clinical PET/CT imaging involving 23 patients with suspected prostate cancer, no adverse reactions or significant changes in vital signs were observed, underscoring the safety of both tracers. Notably, 64Cu-NOTA-PSMA-3Q demonstrated higher uptake in the lacrimal glands (17.73 vs. 10.84), parotid glands (20.98 vs. 16.30), and submandibular glands (20.26 vs. 17.28) compared to 64Cu-DOTA-PSMA-3Q. Conversely, uptake in the sublingual glands was lower for 64Cu-NOTA-PSMA-3Q (7.10 vs. 7.49). Of particular clinical relevance, liver uptake of 64Cu-NOTA-PSMA-3Q was significantly lower than that of 64Cu-DOTA-PSMA-3Q (4.04 vs. 8.18), highlighting a key difference in their biodistribution profiles. CONCLUSIONS: Both NOTA and DOTA are suitable chelators for the development of 64Cu-labeled PSMA-3Q tracers for PET/CT imaging. DOTA showed better tumor retention 24 h after injection, while NOTA showed lower uptake in the liver, in addition, NOTA was higher uptake in the salivary glands, while DOTA was lower uptake in these tissues. Overall, these findings highlight the importance of selecting the right chelating agent to optimize clinical imaging outcomes. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300072655, Registered 20 June 2023.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu H, Zhang X, Zhang J, et al. Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging. Eur J Nucl Med Mol Imaging. 2025. PMID: 39954062. doi:10.1007/s00259-025-07131-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。